$5.4 million boost for brain cancer research

The Australian Government will invest more than $5.4 million in three ground-breaking brain cancer research projects.

The Hon Mark Butler MP
Minister for Health and Aged Care

Media event date:
Date published:
Media type:
Media release
General public

The Australian Government will invest more than $5.4 million in three groundbreaking brain cancer research projects. 

These projects will improve the health and wellbeing of the almost 2,000 Australians, including up to 200 children, that are diagnosed with this devastating disease each year. 

One of the three projects awarded is the ‘GLIMMER’ project led by the Walter and Eliza Hall Institute of Medical Research. This large-scale project will address the lack of effective treatment options for glioblastoma, the most common and deadliest type of brain cancer. 

The program aims to improve survival outcomes for brain cancer patients and their quality of life, and avoid unnecessary health burdens for this devastating disease. 

The recipients of the 2021 Brain Cancer Research grant, which is part of the Medical Research Future Fund are: 

The Walter and Eliza Hall Institute of Medical Research will receive $4.6 million for its “GLIMMER” - Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform. 

The University of New South Wales will receive $580,000 for a new targeted combination therapy with matched biomarker to treat intractable glioblastoma. 

The Council of the Queensland Institute of Medical Research will receive $330,000 for Off-the-shelf: CAR-T cell immunotherapy for brain cancer. 

Further details about the three projects can be found here.  

Quotes attributable to Minister Butler:  

“Our investment in these three research projects will help Australia, and the rest of the world, tackle brain cancer. 

“Australia has some of the world’s best medical researchers and the Government is proud to support their important work.” 

Related ministers:

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.